Although we show that nintedanib has anti-lymphangiogenic activity, this compound was previously reported to not inhibit tumor lymphangiogenesis in a transgenic mouse model of pancreatic neuroendocrine tumor (PNET) that was genetically engineered to overexpress VEGF-C [32]. The gene discussed is VEGFC; the disease is neoplasm.